Table 4. Clinical characteristics and Gal-3 plasma levels at baseline and 6 months after catheter ablation in patients with and without AF recurrences.
| ERAF* | LRAF# | |||||
|---|---|---|---|---|---|---|
| Yes (n = 40) | No (n = 55) | P-value | Yes (n = 36) | No (n = 56) | P-value | |
| Age, years | 61 ± 9 | 63 ± 10 | 0.382 | 63 ± 9 | 61 ± 10 | 0.429 |
| Males (%) | 68 | 66 | 0.835 | 69 | 64 | 0.609 |
| Paroxysmal AF (%) | 40 | 62 | 0.035 | 42 | 61 | 0.074 |
| Lone AF (%) | 68 | 76 | 0.339 | 61 | 80 | 0.043 |
| AF history, months (median, IQR) | 60 (2–480) | 60 (3–540) | 0.888 | 36 (2–216) | 60 (3–540) | 0.181 |
| CHADS2 (median, IQR) | 1 (0–4) | 1 (0–4) | 0.919 | 1 (0–4) | 1 (0–3) | 0.016 |
| CHA2DS2-VASc (median, IQR) | 2 (0–7) | 2 (0–6) | 0.541 | 2 (0–7) | 2 (0–6) | 0.207 |
| BMI | 29 ± 5 | 29 ± 5 | 0.687 | 30 ± 6 | 28 ± 5 | 0.156 |
| LAD, mm | 43 ± 7 | 42 ± 6 | 0.395 | 43 ± 7 | 41 ± 6 | 0.248 |
| LVEF, % | 60 ± 10 | 60 ± 7 | 0.708 | 60 ± 11 | 60 ± 7 | 0.901 |
| eGFR, ml/min | 100 ± 37 | 94 ± 26 | 0.343 | 95 ± 36 | 98 ± 28 | 0.671 |
| Baseline Gal-3, ng/ml | 7.47 ± 2.40 | 8.01 ± 3.37 | 0.382 | 7.08 ± 2.67 | 8.09 ± 3.15 | 0.115 |
| FU Gal-3, ng/ml | - | - | - | 7.09 ± 2.75 | 8.11 ± 3.13 | 0.111 |
Abbreviations: as in the Table 1, ERAF—early AF recurrences, LRAF—late AF recurrences, FU—6 months follow-up.
*Data available in 95 patients
#Data available in 92 patients